PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML

NCT04722952 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Immunotherapy
Refractory Leukemia
Relapsed Adult AML
Acute Myeloid Leukemia

Interventions

DRUG: Visilizumab

Sponsor

The First Affiliated Hospital of Soochow University